Female Reproductive System Adenocarcinoma

Female Reproductive System Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

454 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 158
Recruiting: 74
Ph III recruiting: 10
Growth YoY: +19%
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: 33.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (59)

clinicaltrialsPublishedShowing 1–50 of 52 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02446600	Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	Phase 3	579	National Cancer Institute (NCI)NIH	4	Sep 29, 2026	clinicaltrials
NCT02502266	Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer	active not recruiting	Phase 2 / Phase 3	582	National Cancer Institute (NCI)